Published in Pharmacogenomics J on April 07, 2015
Sequenced Treatment Alternatives to Relieve Depression (STAR*D) | NCT00021528
Proliferation rates and gene expression profiles in human lymphoblastoid cell lines from patients with depression characterized in response to antidepressant drug therapy. Transl Psychiatry (2016) 0.77
Decreased sensitivity to paroxetine-induced inhibition of peripheral blood mononuclear cell growth in depressed and antidepressant treatment-resistant patients. Transl Psychiatry (2016) 0.76
Microarray analysis of differentially expressed genes and their functions in omental visceral adipose tissues of pregnant women with vs. without gestational diabetes mellitus. Biomed Rep (2017) 0.75
Neuroplasticity and second messenger pathways in antidepressant efficacy: pharmacogenetic results from a prospective trial investigating treatment resistance. Eur Arch Psychiatry Clin Neurosci (2017) 0.75
PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet (2007) 209.92
The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry (1998) 65.11
Neuropilin is a semaphorin III receptor. Cell (1997) 4.88
Neural recognition molecules of the immunoglobulin superfamily: signaling transducers of axon guidance and neuronal migration. Nat Neurosci (2007) 4.06
Psychosocial disability during the long-term course of unipolar major depressive disorder. Arch Gen Psychiatry (2000) 3.73
Data quality control in genetic case-control association studies. Nat Protoc (2010) 3.68
VEGF is an essential mediator of the neurogenic and behavioral actions of antidepressants. Proc Natl Acad Sci U S A (2007) 2.22
Contribution of common genetic variants to antidepressant response. Biol Psychiatry (2012) 1.73
Epigenetic regulation of RAC1 induces synaptic remodeling in stress disorders and depression. Nat Med (2013) 1.70
Pharmacologically diverse antidepressants rapidly activate brain-derived neurotrophic factor receptor TrkB and induce phospholipase-Cgamma signaling pathways in mouse brain. Neuropsychopharmacology (2007) 1.64
Clinical factors associated with treatment resistance in major depressive disorder: results from a European multicenter study. J Clin Psychiatry (2007) 1.60
Interactions between integrin alphaIIbbeta3 and the serotonin transporter regulate serotonin transport and platelet aggregation in mice and humans. J Clin Invest (2008) 1.57
Semaphorin function in neural plasticity and disease. Curr Opin Neurobiol (2009) 1.48
Confirmed rare copy number variants implicate novel genes in schizophrenia. Biochem Soc Trans (2010) 1.42
VEGF as a potential target for therapeutic intervention in depression. Curr Opin Pharmacol (2007) 1.41
Gender differences in depression. Int Rev Psychiatry (2010) 1.40
Familial concordance of fluvoxamine response as a tool for differentiating mood disorder pedigrees. J Psychiatr Res (1999) 1.25
Targeting glycogen synthase kinase-3 in the CNS: implications for the development of new treatments for mood disorders. Curr Drug Targets (2006) 1.23
Neuroplasticity in the olfactory system: differential effects of central and peripheral lesions of the primary olfactory pathway on the expression of B-50/GAP43 and the olfactory marker protein. J Neurosci Res (1990) 1.14
Modulation of synaptic plasticity in the hippocampus by hippocampus-derived estrogen and androgen. J Steroid Biochem Mol Biol (2011) 1.11
Resistance to change and vulnerability to stress: autistic-like features of GAP43-deficient mice. Genes Brain Behav (2010) 1.11
DHHC-7 and -21 are palmitoylacyltransferases for sex steroid receptors. Mol Biol Cell (2011) 1.04
Differential involvement of beta3 integrin in pre- and postsynaptic forms of adaptation to chronic activity deprivation. Neuron Glia Biol (2009) 1.02
Genome-wide expression profiling of human lymphoblastoid cell lines identifies CHL1 as a putative SSRI antidepressant response biomarker. Pharmacogenomics (2011) 0.99
L1 and CHL1 Cooperate in Thalamocortical Axon Targeting. Cereb Cortex (2010) 0.97
Reduced reactivity to novelty, impaired social behavior, and enhanced basal synaptic excitatory activity in perforant path projections to the dentate gyrus in young adult mice deficient in the neural cell adhesion molecule CHL1. Mol Cell Neurosci (2006) 0.95
Copy number variant study of bipolar disorder in Canadian and UK populations implicates synaptic genes. Am J Med Genet B Neuropsychiatr Genet (2014) 0.94
An integrated genomic analysis of gene-function correlation on schizophrenia susceptibility genes. J Hum Genet (2010) 0.93
β3 integrin interacts directly with GluA2 AMPA receptor subunit and regulates AMPA receptor expression in hippocampal neurons. Proc Natl Acad Sci U S A (2012) 0.93
Genome-wide miRNA expression profiling of human lymphoblastoid cell lines identifies tentative SSRI antidepressant response biomarkers. Pharmacogenomics (2012) 0.93
Lack of change in markers of presynaptic terminal abundance alongside subtle reductions in markers of presynaptic terminal plasticity in prefrontal cortex of schizophrenia patients. Biol Psychiatry (2011) 0.90
Emerging complexity of the HuD/ELAVl4 gene; implications for neuronal development, function, and dysfunction. RNA (2013) 0.90
Genome-wide expression profiling of human lymphoblastoid cell lines implicates integrin beta-3 in the mode of action of antidepressants. Transl Psychiatry (2013) 0.89
Antidepressants stimulate hippocampal neurogenesis by inhibiting p21 expression in the subgranular zone of the hipppocampus. PLoS One (2011) 0.88
GAP43 phosphorylation is critical for growth and branching of retinotectal arbors in zebrafish. Dev Neurobiol (2010) 0.86
Elevated gene expression of glutamate receptors in noradrenergic neurons from the locus coeruleus in major depression. Int J Neuropsychopharmacol (2014) 0.85
Biological predictors of lithium response in bipolar disorder. Psychiatry Clin Neurosci (2003) 0.84
Serotonin transporter and integrin beta 3 genes interact to modulate serotonin uptake in mouse brain. Neurochem Int (2013) 0.83
Gene expression analysis of novel genes in the prefrontal cortex of major depressive disorder subjects. Prog Neuropsychopharmacol Biol Psychiatry (2012) 0.83
The need for clinically relevant research on treatment-resistant depression. J Clin Psychiatry (2001) 0.81
Increased hippocampal neurogenesis and p21 expression in depression: dependent on antidepressants, sex, age, and antipsychotic exposure. Neuropsychopharmacology (2013) 0.81
CHL1 cooperates with PAK1-3 to regulate morphological differentiation of embryonic cortical neurons. Neuroscience (2009) 0.81
Integrin β3 Haploinsufficiency Modulates Serotonin Transport and Antidepressant-Sensitive Behavior in Mice. Neuropsychopharmacology (2015) 0.81
Early antidepressant efficacy modulation by glutamatergic gene variants in the STAR*D. Eur Neuropsychopharmacol (2012) 0.80
Family-based association study of ITGB3 in autism spectrum disorder and its endophenotypes. Eur J Hum Genet (2010) 0.80
Stress downregulates hippocampal expression of the adhesion molecules NCAM and CHL1 in mice by mechanisms independent of DNA methylation of their promoters. Cell Adh Migr (2008) 0.79
PPP3CC gene: a putative modulator of antidepressant response through the B-cell receptor signaling pathway. Pharmacogenomics J (2014) 0.79
Sequenced Treatment Alternatives to Relieve Depression (STAR*D). Part 1: study design. J Psychosoc Nurs Ment Health Serv (2008) 0.78
Genetic association analysis of ITGB3 polymorphisms with age at onset of schizophrenia. J Mol Neurosci (2013) 0.77
Clinical features and drug induced side effects in early versus late antidepressant responders. J Psychiatr Res (2013) 0.76
PPP3CC gene: a putative modulator of antidepressant response through the B-cell receptor signaling pathway. Pharmacogenomics J (2014) 0.79
Collaborative meta-analysis finds no evidence of a strong interaction between stress and 5-HTTLPR genotype contributing to the development of depression. Mol Psychiatry (2017) 0.76
Genomewide interaction and enrichment analysis on antidepressant response. Psychol Med (2013) 0.75
Genetic variants in combination with early partial improvement as a clinical utility predictor of treatment outcome in major depressive disorder: the result of two pooled RCTs. Transl Psychiatry (2015) 0.75
Expansion and further delineation of the SETD5 phenotype leading to global developmental delay, variable dysmorphic features, and reduced penetrance. Clin Genet (2017) 0.75